Search -

Displaying 1 - 20 of 136

Sort: Relevancy | Date

Presentation TCT 2025

TCT 1521: Extremely Early Tricuspid Bioprosthetic Valve Degeneration: Diagnostic Evaluation and Successful Transcatheter Valve-in-Valve Intervention

Presenter: Mark Sonbol

October 28, 2025

Presentation TCT 2025

Challenging Surgical Valves for TAV in SAV: Mitraflow, Trifecta, Stentless Valves and Homografts

Presenter: Keith B. Allen

October 27, 2025

Presentation TCT 2025

Leaflet Modification: When and How?

Presenter: Pedro Arturo Villablanca

October 27, 2025

Presentation TCT 2025

Bioprosthetic Valve Fracture: Benefits and Risks

Presenter: Santiago Garcia

October 27, 2025

Presentation TCT 2025

Procedural Planning for ViV TAVR

Presenter: Chad Alan Kliger

October 27, 2025

Presentation TCT 2025

Long Term Outcomes After TAV in SAVR: Do We Need A Randomized Trial?

Presenter: Michael A. Borger

October 27, 2025

Presentation TCT 2025

TCT 758: Lp(a) and Oxidized Phospholipids as Predictors of Bioprosthetic Valve Dysfunction Following Transcatheter Aortic Valve Implantation

Presenter: Frédéric Beaupré

October 27, 2025

Presentation TCT 2025

TCT 1226: Valve-in-Valve TAVR for Failed Trifecta Surgical Bioprosthetic Aortic Valves

Presenter: Matjaz Bunc

October 26, 2025

Presentation TCT 2025

Featured Clinical Research: Prediction Models for the Treatment of Bioprosthetic Aortic Valve Failure in the United States

Presenter: Philippe Genereux

October 26, 2025

Presentation TCT 2025

TCT 1222: Bioprosthetic Valve Fracture During VIV TAVR with a Self-Expanding Evolut Valve: Safety and Hemodynamics Outcomes from the Transcatheter Valve Therapy Registry

Presenter: Keith B. Allen

October 26, 2025

Presentation TCT 2025

TCT 882: Impact of Different Leaflet and Stent Materials on Bileaflet Bioprosthetic Mitral Valve Performance

Presenter: Joseph Chibuike Nwokeafor

October 26, 2025

Presentation TCT 2025

TCT 1531: Transfemoral Tricuspid Valve-in-Valve (ViV) Procedure in a High-Risk Patient With Bioprosthetic Valve Failure and Prior Infective Endocarditis

Presenter: Khin May Thaw

October 25, 2025

Presentation TCT 2025

TCT 1103: Transcatheter vs. Surgical Replacement of Degenerated Bioprosthetic Aortic Valve Over Time: Findings from a Meta-Analysis of Propensity-Score-Matched Studies

Presenter: Mohammad Javad Namazi

October 25, 2025

Presentation TCT 2025

TCT 229: Association Between Early Bioprosthetic Valve Dysfunction and Long-Term Clinical Outcomes After Transcatheter Aortic Valve Replacement

Presenter: Dhaval Kolte

October 25, 2025

Presentation TCT 2025

TCT 1302: LAVA-ECMO Supported ViV TAVR and PVL Closure in Aortic Bioprosthetic Valve Dehiscence

Presenter: Hon Yeung Ko

October 25, 2025

Presentation TCT 2025

TCT 5: A Novel Nanomaterial Surface Coating for Bioactive Drug Functionalisation of Bioprosthetic Heart Valves

Presenter: Richard Tan

October 25, 2025

Presentation TCT 2024

TCT 870: Prediction Models for the Treatment of Bioprosthetic Aortic Valve Failure in the United States

Presenter: Philippe Genereux

October 30, 2024

Presentation TCT 2024

Late Clinical Outcomes in Small Annulus Patients in the PARTNER Trials

Presenter: Mahesh Madhavan

October 30, 2024

Presentation TCT 2024

Prosthesis-Patient Mismatch: Definitions, Incidence, and Clinical Relevance in SAVR and TAVR Patients

Presenter: Julien Ternacle

October 30, 2024

Presentation TCT 2024

Fifty Shades of Gray: The “Correct” Way to Diagnose Bioprosthetic Valve Durability

Presenter: Philippe Pibarot

October 30, 2024

Advertisement

TCT 1521: Extremely Early Tricuspid Bioprosthetic Valve Degeneration: Diagnostic Evaluation and Successful Transcatheter Valve-in-Valve Intervention

Challenging Surgical Valves for TAV in SAV: Mitraflow, Trifecta, Stentless Valves and Homografts

Leaflet Modification: When and How?

Bioprosthetic Valve Fracture: Benefits and Risks

Procedural Planning for ViV TAVR

Long Term Outcomes After TAV in SAVR: Do We Need A Randomized Trial?

TCT 758: Lp(a) and Oxidized Phospholipids as Predictors of Bioprosthetic Valve Dysfunction Following Transcatheter Aortic Valve Implantation

TCT 1226: Valve-in-Valve TAVR for Failed Trifecta Surgical Bioprosthetic Aortic Valves

Featured Clinical Research: Prediction Models for the Treatment of Bioprosthetic Aortic Valve Failure in the United States

TCT 1222: Bioprosthetic Valve Fracture During VIV TAVR with a Self-Expanding Evolut Valve: Safety and Hemodynamics Outcomes from the Transcatheter Valve Therapy Registry

TCT 882: Impact of Different Leaflet and Stent Materials on Bileaflet Bioprosthetic Mitral Valve Performance

TCT 1531: Transfemoral Tricuspid Valve-in-Valve (ViV) Procedure in a High-Risk Patient With Bioprosthetic Valve Failure and Prior Infective Endocarditis

TCT 1103: Transcatheter vs. Surgical Replacement of Degenerated Bioprosthetic Aortic Valve Over Time: Findings from a Meta-Analysis of Propensity-Score-Matched Studies

TCT 229: Association Between Early Bioprosthetic Valve Dysfunction and Long-Term Clinical Outcomes After Transcatheter Aortic Valve Replacement

TCT 1302: LAVA-ECMO Supported ViV TAVR and PVL Closure in Aortic Bioprosthetic Valve Dehiscence

TCT 5: A Novel Nanomaterial Surface Coating for Bioactive Drug Functionalisation of Bioprosthetic Heart Valves

TCT 870: Prediction Models for the Treatment of Bioprosthetic Aortic Valve Failure in the United States

Late Clinical Outcomes in Small Annulus Patients in the PARTNER Trials

Prosthesis-Patient Mismatch: Definitions, Incidence, and Clinical Relevance in SAVR and TAVR Patients

Fifty Shades of Gray: The “Correct” Way to Diagnose Bioprosthetic Valve Durability

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content